Acquisition brings Benzer to Empire State
Benzer Pharmacy’s latest acquisition is marking the company’s entry into New York state. The Tampa, Fla.-based company recently finalized the purchase of Amenia, N.Y. drug store Drug World Pharmacy.
Benzer acquisition manager Carly Tan said that the New York market has been in Benzer’s crosshairs for years, with a beginning goal of establishing an introductory footprint in the Empire State.
“The Benzer Pharmacy acquisitions department believes the acquisition of Drug World Pharmacy in Amenia, New York is a symbol of what’s to come in the Northeast and across the country,” Tan said. “That mission will continue as we seek to increase the number and visibility of Benzer Pharmacy locations on a state-by-state and region-by-region basis in the months and years ahead.”
Benzer now operates more than 65 corporate locations and has roughly 20 franchisee locations in 10 states.
Strides’ generic Tamiflu approved
The Food and Drug Administration has approved Strides Pharma’s generic Tamiflu capsules (oseltamivir phosphate capsules). The drug is indicated to treat symptoms caused by the flu virus and shorten recovery time.
The Strides Shasun subsidiary said that the product has seen volume growth in the past year due to a strong flu season. IQVIA data shows a market size for generic Tamiflu of roughly $725 million for the 12 months ended April 2018. Strides said the product would be manufactured at its oral dosage facility and Bangalore.
The product will be available in 30-, 45- and 75-mg (base) dosage strengths.
Glenmark gets FDA OK for Hailey, Hailey Fe
The Food and Driug Administration has approved two birth control products for Glenmark’s branded generics of Loestrin 21 and Loestrin Fe 1.5/30. The company’s Hailey (norethindrone acetate and ethinyl estradiol tablets 1.5 mg/30 mcg) and Hailey Fe (norethindrone acetate and ethinyl estradiol tablets, 1.5 mg) USP and ferrous fumarate tablets, 1.5 mg/30 mcg) are indicated to prevent pregnancy in women.
Hailey will enter a market whose size was roughly $24.2 million for the 12 months ended April 2018, and Hailey Fe will enter a roughly $41.3 million market for the 12 months ended April 2018, according to IQVIA data. Glenmark said it currently has 61 generic applications pending before the FDA.